BioStem Technologies, Inc. (OTC: BSEM) has received Notice of Allowance from the United States Patent and Trademark Office (USPTO) for three new patents covering the company's innovative fenestrated human placental allograft designs and compositions. The patents represent a significant advancement in wound care technology, utilizing the company's proprietary BioREtain® processing method to create next-generation placental allografts.
Patent Portfolio Expansion
The USPTO issued Notice of Allowance for two design patents (Application Nos. 29/860,417 and 29/860,420) for "FENESTRATED HUMAN PLACENTAL ALLOGRAFT" and one utility patent (Application No. 18/926,867) for "STERILE HUMAN PLACENTAL ALLOGRAFTS HAVING A PLURALITY OF SLITS, OPENINGS, AND/OR FENESTRATIONS FORMED THEREON." These patents expand BioStem's intellectual property portfolio to 55 issued patents and 52 pending applications.
Innovative Fenestration Technology
The patented fenestrated design represents a breakthrough in allograft technology. The unique fenestration pattern allows wound exudate to pass through the graft and away from the wound without sacrificing allograft area, thereby facilitating drainage and providing an environment that is more conducive to healing. This design addresses a critical challenge in wound care by optimizing fluid management while maintaining the therapeutic benefits of placental tissue.
BioREtain® Process Advantages
The fenestrated allografts are manufactured using BioStem's proprietary BioREtain® process, which preserves the structural and molecular integrity of the amnion and chorion tissues. This method of preparation facilitates and enhances wound treatment compared to conventional human placental allografts, particularly in the treatment of diabetic foot ulcers, dental wounds, and other topical wounds.
Clinical Applications and Market Impact
The technology specifically targets challenging wound types including diabetic foot ulcers, dental wounds, and other topical wounds. By optimizing the retention and preservation of the amnion, intermediate, and chorion layers, the company aims to offer clinicians solutions that support better outcomes and improve patient care.
Jason Matuszewski, Chief Executive Officer of BioStem Technologies, commented: "BioStem is actively expanding its patent portfolio to accelerate product innovation and drive the development of new products that elevate the standard of wound care. These newly granted patents play a pivotal role in the advancement of our next-generation placental allograft technologies and underscore the proprietary nature of our BioREtain process - designed to preserve the structural and molecular integrity of the placental tissue."
Company Profile and Manufacturing
BioStem Technologies operates as a leading MedTech company focused on the development, manufacturing, and commercialization of placental-derived products for advanced wound care. The company's quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks (AATB), with systems established per current Good Tissue Practices (cGTP) and current Good Manufacturing Processes (cGMP).
The company's product portfolio includes AmnioWrap2™, VENDAJE®, VENDAJE AC®, and VENDAJE OPTIC®. Each BioStem Technologies placental allograft is processed at the company's FDA registered and AATB accredited facility in Pompano Beach, Florida.
